Health
New study shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer. – Brinkwire
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The data is published today in Cancer Research, a journal of the American Associat…
-
General23 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News23 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
General24 hours agoLithium mine closure shines light on Ravensthorpe community’s resilience
-
Noosa News18 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan